The current state of radiotherapeutics is “the isotope wars” according to Jack Hoppin, CEO of Boston’s Ratio Therapeutics.

The current state of radiotherapeutics is “the isotope wars” according to Jack Hoppin, CEO of Boston’s Ratio Therapeutics.

As the biopharma industry heads into 2026, insights gained over the past year are set to be applied and scaled, especially in ...

Anthropic has launched Claude for Healthcare, a suite of AI tools for health systems, payers, and patients, in the latest ...

AbbVie has joined many of its big pharma peers by signing a Most-Favoured Nation (MFN) drug pricing deal with the Trump ...

The US regulator has approved Sentynl Therapeutics Zycubo (copper histidinate; formerly known as CUTX-101) as a treatment for ...

The data was revealed as a UK delegation headed by MHRA chief executive Lawrence Tallon attended the J PM Healthcare ...

At the Sachs Neuroscience Forum just before the start of the JP Morgan Healthcare Conference in San Francisco, pharmaphorum’s ...

Laboratories are no longer peripheral. They are central to modern clinical development - enabling earlier decision-making, ...

French newspaper La Lettre said the Paris-based biotech – which is listed on the Nasdaq – has been on Lilly's radar after ...

Jiangsu Hengrui Pharma has chalked up a first-in-class approval for retlirafusp alfa, a bifunctional drug that targets PD-L1 and TGF-beta, as a treatment for advanced gastric cancer. The green light – ...

The licensing agreement, which includes a big upfront payment of $650 million and milestone payments of up to $4.95 billion, ...